Ascletis clinical site
San Antonio, Texas, 78209, United States
NCT Number: NCT06679959
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1 / Phase 2
San Antonio, Texas, 78209, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Drug: ASC30 injection, for subcutaneous use Drug: Placebo injection, for subcutaneous use
Time frame: Up to Day169
A summary of AEs, SAEs and other non-serious adverse events
Time frame: Up to Day169
PK parameters of ASC30
Time frame: Up to Day169
Change From Baseline in Body Weight
Ascletis Pharma (China) Co., Limited
Industry
A Phase I/IIa, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Injection, for Subcutaneous Use in Participants With Obesity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06703021
Body Weight, Chronic Weight Management
Glendale, California, United States
View Trial DetailsNCT06972992
Chronic Weight Management
San Antonio, Texas, United States
View Trial DetailsNCT07002905
Chronic Weight Management
Rogers, Arkansas, United States
View Trial DetailsNCT06671821
Chronic Weight Management
Beijing, Beijing Municipality, China
View Trial Details